Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Atezolizumab |
| Synonyms | |
| Therapy Description |
Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with advanced urothelial carcinoma, metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound for advanced or metastatic triple-negative breast cancer expressing PD-L1, and in combination with carboplatin and etoposide for small cell lung cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Atezolizumab | Tecentriq | RG7446|MPDL3280A | Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 65 | Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy or progressed on platinum-based chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>=50% or IC>=10%) and without EGFR or ALK alterations, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound in advanced or metastatic triple-negative breast cancer expressing PD-L1, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, and in combination with cobimetinib and vemurafenib in BRAF V600-mutated melanoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK rearrange | lung non-small cell carcinoma | no benefit | Atezolizumab | Guideline | Actionable | Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org). | detail... |
| ALK rearrange | lung non-small cell carcinoma | no benefit | Atezolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694). | 27225694 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | Atezolizumab | Phase II | Actionable | In a Phase II trial (POPLAR), treatment with Tecentriq (atezolizumab) resulted in an improved median overall survival of 12.6 months compared to 9.7 months with Taxotere (docetaxel) in patients with previously treated non-small cell lung cancer, and increased PD-L1 expression level was associated with improved survival benefit (PMID: 26970723; NCT01903993). | 26970723 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | Atezolizumab | FDA approved | Actionable | In a Phase III trial (OAK) that supported FDA approval, treatment with Tecentriq (atezolizumab) resulted in an improved median overall survival compared to Taxotere (docetaxel) (13.8 vs 9.6 months, HR=0.73, p=0.0003) in patients with previously treated non-small cell lung cancer (PMID: 27979383; NCT02008227). | detail... 27979383 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | Atezolizumab | Clinical Study - Meta-analysis | Actionable | In a meta-analysis, compared to Taxotere (docetaxel), treatment with immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival (HR=0.69, p<0.001) in non-small cell lung carcinoma patients (PMID: 29270615). | 29270615 |
| ARID1A mutant | bladder urothelial carcinoma | predicted - sensitive | Atezolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, metastatic urothelial carcinoma patients from the IMvigor210 trial harboring an ARID1A mutation (n=62) demonstrated a greater overall survival (15.4 mo vs 8.2 mo; P=0.03) compared to patients with wild-type ARID1A (n=213) when treated with Tecentriq (atezolizumab) (PMID: 32554706; NCT02108652). | 32554706 |
| Unknown unknown | colorectal cancer | no benefit | Atezolizumab | Phase III | Actionable | In a Phase III trial (IMblaze370), Tecentriq (atezolizumab) treatment did not improve median overall survival (7.1 vs 8.5 months, HR=1.19) compared to Stivarga (regorafenib) in patients with chemotherapy-refractory metastatic colorectal cancer, 91.7% of whom were microsatellite stable or microsatellite instability-low (Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018; NCT02788279). | detail... |
| ERBB2 act mut | lung non-small cell carcinoma | decreased response | Atezolizumab | Clinical Study - Cohort | Actionable | In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721). | 31085721 |
| FGFR3 mutant | transitional cell carcinoma | no benefit | Atezolizumab | Phase II | Actionable | In a Phase II trial (IMVigor 210, CheckMate 275), Tecentriq (atezolizumab) (n=119) treatment resulted in similar response rate (24% vs 21%, p=0.8) in patients with FGFR3 mutant or wild-type metastatic transitional cell carcinoma (PMID: 31272788). | 31272788 |
| Unknown unknown | urinary bladder cancer | no benefit | Atezolizumab | Phase III | Actionable | In a Phase III trial, Tecentriq (atezolizumab) did not result in improved survival in patients with bladder cancer (PMID: 28559560). | 28559560 |
| Unknown unknown | transitional cell carcinoma | not applicable | Atezolizumab | FDA approved | Actionable | In a Phase II trial that supported FDA approval, treatment with Tecentriq (atezolizumab) in advanced urothelial carcinoma patients resulted in an objective response rate of 15% (45/310) in all patients, and 26% (26/100) in patients with immune cell PD-L1 expression greater than or equal to 5%, and resulted in an overall survival of 8.6 mo in patients receiving treatment post-progression compared to 1.2 mo in patients receiving no treatment post-progression (PMID: 26952546, PMID: 28950298; NCT02108652). | 26952546 28950298 detail... |
| Unknown unknown | invasive bladder transitional cell carcinoma | no benefit | Atezolizumab | Phase III | Actionable | In a Phase III trial (IMvigor010). adjuvant Tecentriq (atezolizumab) did not improve disease-free survival (HR=0.89, p=0.2446) or overall survival (HR=0.85, p=0.1951) compared to observation in patients with high-risk muscle-invasive urothelial carcinoma, and resulted in more treatment discontinuation due to adverse effects than previous studies (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 5000-5000; NCT02450331). | detail... |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status |
|---|---|---|---|---|
| NCT03029832 | Phase II | Atezolizumab Atezolizumab + MOXR0916 | A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy | Terminated |
| NCT03821246 | Phase II | Atezolizumab + Emactuzumab Atezolizumab Atezolizumab + Enzalutamide | Neoadjuvant Atezolizumab With or Without Enzalutamide in Localized Prostate Cancer Given Before Radical Prostatectomy | Recruiting |
| NCT04214262 | Phase III | Atezolizumab | Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer | Recruiting |
| NCT02508870 | Phase I | Azacitidine Atezolizumab | A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes | Completed |
| NCT03024437 | Phase Ib/II | Atezolizumab + Entinostat Atezolizumab + Bevacizumab + Entinostat Atezolizumab | Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma | Recruiting |
| NCT02589717 | FDA approved | Atezolizumab | An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy | Approved for marketing |
| NCT03141684 | Phase II | Atezolizumab | Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery | Recruiting |
| NCT03191786 | Phase III | Atezolizumab Gemcitabine Vinorelbine | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naive Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS) | Active, not recruiting |
| NCT02091141 | Phase II | Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | Active, not recruiting |
| NCT03340558 | Phase II | Atezolizumab Atezolizumab + Cobimetinib | Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer (ATELIER) | Withdrawn |
| NCT04477759 | Phase I | Atezolizumab | Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer (DEHART) | Not yet recruiting |
| NCT02450331 | Phase III | Atezolizumab | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010) | Active, not recruiting |
| NCT03513952 | Phase II | Atezolizumab + CYT107 Atezolizumab | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | Recruiting |
| NCT03120676 | Phase II | Atezolizumab | Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma | Terminated |
| NCT03024996 | Phase III | Atezolizumab | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) | Active, not recruiting |
| NCT02471846 | Phase I | GDC-0919 Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed |
| NCT02844816 | Phase II | Atezolizumab | Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer | Active, not recruiting |
| NCT04387084 | Phase I | Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | Not yet recruiting |
| NCT04294810 | Phase III | Atezolizumab Atezolizumab + MTIG7192A | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01) | Recruiting |
| NCT02400814 | Phase I | Atezolizumab | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer | Active, not recruiting |
| NCT02367781 | Phase III | Atezolizumab Carboplatin + Nab-paclitaxel | A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer | Completed |
| NCT03473756 | Phase Ib/II | Atezolizumab Atezolizumab + Rogaratinib | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) | Recruiting |
| NCT02304393 | Phase I | Selicrelumab Atezolizumab | A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors | Completed |
| NCT01903993 | Phase II | Atezolizumab | A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" | Completed |
| NCT03424005 | Phase Ib/II | Atezolizumab + Bevacizumab + Selicrelumab Atezolizumab + RO6874281 Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Eribulin Capecitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + Ladiratuzumab vedotin | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) | Recruiting |
| NCT03197935 | Phase III | Pegfilgrastim Doxorubicin Atezolizumab Filgrastim Nab-paclitaxel Cyclophosphamide | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) | Active, not recruiting |
| NCT03452137 | Phase III | Atezolizumab | A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck | Recruiting |
| NCT02784483 | Phase I | Atezolizumab | Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma | Terminated |
| NCT03555149 | Phase Ib/II | Atezolizumab Atezolizumab + Isatuximab Atezolizumab + Bevacizumab + PGG beta-glucan | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | Recruiting |
| NCT04300647 | Phase II | Atezolizumab Atezolizumab + MTIG7192A | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04) | Recruiting |
| NCT02486718 | Phase III | Atezolizumab | Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer | Active, not recruiting |
| NCT04402788 | Phase II | Atezolizumab Atezolizumab + Radiotherapy | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Recruiting |
| NCT02008227 | Phase III | Docetaxel Atezolizumab | A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK | Completed |
| NCT02420821 | Phase III | Bevacizumab Sunitinib Atezolizumab | A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | Active, not recruiting |
| NCT04157985 | Phase III | Nivolumab Ipilimumab Pembrolizumab Atezolizumab | Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors | Recruiting |
| NCT03148418 | Phase II | Atezolizumab | A Study in Participants Previously Enrolled in a Genentech? and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study | Recruiting |
| NCT02792192 | Phase Ib/II | Atezolizumab + BCG solution Atezolizumab | Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants | Active, not recruiting |
| NCT04322643 | Phase II | Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | Recruiting |
| NCT03014648 | Phase II | Atezolizumab | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT02458638 | Phase II | Atezolizumab | An Open Label Study of MPDL3280A in Advanced Solid Tumors | Completed |
| NCT03614949 | Phase II | Atezolizumab | SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer | Recruiting |
| NCT02928406 | Phase III | Atezolizumab | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | Active, not recruiting |
| NCT04267237 | Phase II | Atezolizumab + RO7198457 Atezolizumab | A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | Recruiting |
| NCT04273061 | Phase II | Atezolizumab | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) | Recruiting |
| NCT03178851 | Phase I | Atezolizumab Atezolizumab + Cobimetinib | Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma | Active, not recruiting |
| NCT02410512 | Phase I | MOXR0916 Atezolizumab | A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors | Completed |
| NCT01984242 | Phase II | Atezolizumab Sunitinib Atezolizumab + Bevacizumab + Capecitabine | A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | Completed |
| NCT03237780 | Phase II | Atezolizumab Atezolizumab + Eribulin | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | Recruiting |
| NCT03483012 | Phase II | Atezolizumab | Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis | Recruiting |
| NCT03563716 | Phase II | Atezolizumab + MTIG7192A Atezolizumab | A Study of MTIG7192A in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Active, not recruiting |
| NCT03178552 | Phase II | Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Atezolizumab + Cobimetinib + Vemurafenib Alectinib | A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) | Recruiting |
| NCT02350673 | Phase I | Cergutuzumab amunaleukin Atezolizumab | A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors | Completed |
| NCT03869190 | Phase Ib/II | Atezolizumab + Tocilizumab Atezolizumab + Niraparib Atezolizumab + Hu5F9-G4 Atezolizumab + Enfortumab vedotin-ejfv Atezolizumab + Linagliptin Atezolizumab + Isatuximab Atezolizumab | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS mUC) | Recruiting |
| NCT03465891 | Phase II | Atezolizumab | Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma | Terminated |
| NCT02848651 | Phase II | Atezolizumab | A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST] | Completed |
| NCT03313804 | Phase II | Pembrolizumab Atezolizumab Nivolumab | Priming Immunotherapy in Advanced Disease With Radiation | Recruiting |
| NCT04272645 | Phase II | Abemaciclib + Atezolizumab Abemaciclib Atezolizumab | Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer | Withdrawn |
| NCT02431208 | Phase I | Lenalidomide Atezolizumab | A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM) | Active, not recruiting |
| NCT02599454 | Phase I | Atezolizumab | Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | Active, not recruiting |
| NCT02788279 | Phase III | Atezolizumab Atezolizumab + Cobimetinib Regorafenib | A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma | Completed |
| NCT01375842 | Phase I | Atezolizumab | A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Completed |
| NCT02525757 | Phase II | Atezolizumab Carboplatin + Paclitaxel | MPDL3280A With Chemoradiation for Lung Cancer | Active, not recruiting |
| NCT04543617 | Phase III | Atezolizumab Atezolizumab + MTIG7192A | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (SKYSCRAPER-07) | Not yet recruiting |
| NCT04334941 | Phase II | Atezolizumab + Talazoparib Atezolizumab | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | Recruiting |
| NCT02927301 | Phase II | Atezolizumab | A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting |
| NCT03768063 | FDA approved | Atezolizumab | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) | Recruiting |
| NCT02708680 | Phase Ib/II | Atezolizumab Atezolizumab + Entinostat | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | Active, not recruiting |
| NCT02541604 | Phase I | Atezolizumab | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors | Terminated |
| NCT03201458 | Phase II | Atezolizumab Atezolizumab + Cobimetinib | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery | Active, not recruiting |
| NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Recruiting |
| NCT02409355 | Phase III | Carboplatin Cisplatin Gemcitabine Atezolizumab | A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer | Terminated |
| NCT02031458 | Phase II | Atezolizumab | A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH | Completed |
| NCT02997228 | Phase III | Atezolizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer | Suspended |
| NCT03115801 | Phase II | Atezolizumab Nivolumab | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | Active, not recruiting |
| NCT03979066 | Phase II | Atezolizumab Atezolizumab + PEGPH20 | Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC) | Terminated |
| NCT02302807 | Phase III | Paclitaxel Vinorelbine Atezolizumab Docetaxel | A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | Completed |
| NCT03977467 | Phase II | Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin | Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | Recruiting |
| NCT02367794 | Phase III | Carboplatin Nab-paclitaxel Paclitaxel Atezolizumab | A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting |
| NCT02451423 | Phase II | Atezolizumab | Study of MPDL3280A in Bladder Cancer | Recruiting |
| NCT02463994 | Phase I | Atezolizumab | A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC | Completed |
| NCT03102242 | Phase II | Atezolizumab | Atezolizumab Immunotherapy in Patients With Advanced NSCLC | Active, not recruiting |
| NCT03206047 | Phase Ib/II | Atezolizumab + Guadecitabine Atezolizumab Atezolizumab + Guadecitabine + Rasdegafusp alfa | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting |
| NCT03281954 | Phase III | Atezolizumab | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | Recruiting |
| NCT04310020 | Phase II | Atezolizumab | Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | Recruiting |
| NCT02862275 | Phase 0 | Atezolizumab | Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | Recruiting |
| NCT03023423 | Phase Ib/II | Atezolizumab + Daratumumab Atezolizumab | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX) | Completed |
| NCT02108652 | Phase II | Atezolizumab | A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | Active, not recruiting |
| NCT03708224 | Phase II | Atezolizumab + Emactuzumab Atezolizumab | Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma | Active, not recruiting |
| NCT03337698 | Phase Ib/II | Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + CPI-444 Atezolizumab Atezolizumab + Docetaxel Docetaxel Atezolizumab + Cobimetinib Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + RO6958688 | A Study Evaluating ThA Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus Lung) | Recruiting |
| NCT02409342 | Phase III | Atezolizumab Carboplatin Pemetrexed Disodium Cisplatin | A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting |
| NCT02609984 | Phase II | Atezolizumab G305 + ID-LV305 | Trial of CMB305 and Atezolizumab in Patients With Sarcoma | Terminated |
| NCT03620435 | Phase II | Atezolizumab | Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer | Recruiting |
CKB BOOST